Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
delayed haemolytic transfusion reaction
eculizumab
haemoglobinopathies
hyperhaemolysis
thalassaemia
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
26
05
2021
received:
01
04
2021
accepted:
05
08
2021
pubmed:
17
8
2021
medline:
18
3
2022
entrez:
16
8
2021
Statut:
ppublish
Résumé
Hyperhaemolytic transfusion reactions are rare life-threatening events predominantly affecting patients with haemoglobinopathies. We report two cases in β-thalassaemia major patients on chronic transfusion therapy and highlight the role of eculizumab in its management. Patient 1 presented with intravascular haemolysis on day 7 (D7) post-transfusion and responded to treatment with corticosteroids and intravenous immunoglobulin. However, patient 2 presented with severe symptomatic anaemia (D4 post-transfusion) unresponsive to the aforementioned measures. Eculizumab administration led to resolution of the hyperhaemolysis. We report the successful management of hyperhaemolysis with eculizumab in a β-thalassemia major patient.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
eculizumab
A3ULP0F556
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-414Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. Longo DL, editor. N Engl J Med. 2019;381(2):150-162
Chonat S, Mener A, Verkerke H, Stowell SR. Role of complement in alloimmunization and hyperhemolysis. Curr Opin Hematol. 2020;27(6):406-414.
Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-2781.
European Medicines Agency. Soliris (Eculizumab). https://www.ema.europa.eu/en/documents/overview/soliris-epar-medicine-overview_en.pdf. Accessed April 1, 2021.
Pirenne F. The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease. Curr Opin Hematol. 2019;26(6):488-494.
Win N, Lucas S, Hebballi S, et al. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome. Br J Haematol. 2019;186(3):499-502.
Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol. 2009;68(3):318-319.
National Health System England. Clinical commissioning policy; rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies. https://www.england.nhs.uk/wp-content/uploads/2020/09/1821_Rituximab_Eculizumab_Clinical_Commissioning_Policy.pdf. Accessed April 1, 2021.
Zanetti RC, Vasta LM, Romanelli K, Newton TC. Management of hyperhemolysis in β-thalassemia with multiple immunosuppressives, including complement blockade. J Pediatr Hematol Oncol. 2021. https://doi.org/10.1097/MPH.0000000000002059. Epub ahead of print.
Vagace JM, Cardesa R, Corbacho A, et al. Etiopathological mechanisms and clinical characteristics of hyperhemolysis syndrome in Spanish patients with thalassemia. Ann Hematol. 2016;95(9):1419-1427.